Impact of APE1/ref-1 redox inhibition on pancreatic tumor growth

Molecular Cancer Therapeutics

Volumn 10, Issue 9, 2011, Pages 1698-1708

  Fishel, Melissa L ^a   Jiang, Yanlin ^a   Rajeshkumar, N V ^c   Scandura, Glenda ^d   Sinn, Anthony L ^b   He, Ying ^a   Shen, Changyu ^a   Jones, David R ^a   Pollok, Karen E ^a,b   Ivan, Mircea ^a   Maitra, Anirban ^c   Kelley, Mark R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; E 3330; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REDOX EFFECTOR FACTOR 1; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY; LIVER; LUNG; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PANCREAS; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BENZOQUINONES; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NF-KAPPA B; OXIDATION-REDUCTION; PANCREATIC NEOPLASMS; PROPIONIC ACIDS; TRANSCRIPTION, GENETIC;

EID: 80052815727     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0107     Document Type: Article

References (39)

1. Moore MJ. Chemotherapy in pancreatic carcinoma. Curr Oncol 2003;5:s24-6. (Pubitemid 28446791)
2. Tanase CP, Neagu M, Albulescu R, Hinescu ME. Advances in pancreatic cancer detection. Adv Clin Chem 2010;51:145-80.
3. Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003;2:12.
4. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 2009;11:601-20.
5. Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, et al. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal 2008;10:1853-67.
6. Bapat A, Fishel M, Kelley MR. Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 2009;11:651-68.
7. Kelley MR, Fishel ML. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem 2008;8:417-25. (Pubitemid 351761426)
8. Georgiadis MM, Luo M, Gaur RK, Delaplane S, Li X, Kelley MR. Evolution of the redox function in mammalian apurinic/apyrimidinic endonuclease. Mutat Res 2008;643:54-63.
9. Fishel ML, He Y, Reed AM, Chin-Sinex H, Hutchins GD, Mendonca MS, et al. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst)2008;7:177-86.
10. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007;28:375-95. (Pubitemid 47331610)
11. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007;13:260-7. (Pubitemid 46121878)
12. Tell G, Damante G, Caldwell D, Kelley MR. The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 2005;7:367-84. (Pubitemid 40279805)
13. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000;461:83-108.
14. McNeill DR, Wilson DM 3rd. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 2007;5:61-70.
15. Gorman MA, Morera S, Rothwell DG, De la Fortelle E, Mol CD, Tainer JA, et al. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. Embo J 1997;16:6548-58. (Pubitemid 27483279)
16. Su DG, Delaplane S, Luo M, Rempel DL, Vu B, Kelley MR, et al. Interactions of APE1 with a redox inhibitor: evidence for an alternate conformation of the enzyme. Biochemistry 2011;50:82-92.
17. Kelley MR, Luo M, Reed A, Su D, Delaplane S, Borch R, et al. Functional analysis of novel analogs of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxid Redox Signal 2011;14:1387-401.
18. Luo M, He H, Kelley MR, Georgiadis M. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 2010;12:1247-69.
19. Hiramoto M, Shimizu N, Sugimoto K, Tang J, Kawakami Y, Ito M, et al. Nuclear targeted suppression of NF-kappa B activity by the novel quinone derivative E3330. J Immunol 1998;160:810-9. (Pubitemid 28049322)
20. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, et al. High-performance affinity beads for identifying drug receptors. Nat Biotechnol 2000;18:877-81. (Pubitemid 30640915)
21. Zou GM, Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther 2008;7:2012-21.
22. Jiang Y, Zhou S, Sandusky GE, Kelley MR, Fishel ML. Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest 2010;28:885-95.
23. Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A. The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol 2009;219:209-18.
24. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
25. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, et al. Novel small molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 2010;334:988-98.
26. Fishel ML, Colvin ES, Luo M, Kelley MR, Robertson KA. Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis. Exp Hematol 2010;38:1178-88.
27. Glamann J, Hansen AJ. Dynamic detection of natural killer cell-mediated cytotoxicity and cell adhesion by electrical impedance measurements. Assay Drug Dev Technol 2006;4:555-63. (Pubitemid 46017399)
28. Jiang Y, Guo C, Fishel ML, Wang Z-Y, Vasko MR, Kelley MR. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 2009;8:1273-82.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
30. Fishel ML, Rabik CA, Bleibel WK, Li X, Moschel RC, Dolan ME. Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol 2006;71:239-47. (Pubitemid 41817284)
31. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
32. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?Biochim Biophys Acta 2009;1795:162-72.
33. Burris HA 3rd. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 2005;32:1-3.
34. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007;110:525-33. (Pubitemid 47106140)
35. Garcea G, Doucas H, Steward WP, Dennison AR, Berry DP. Hypoxia and angiogenesis in pancreatic cancer. ANZ J Surg 2006;76:830-42. (Pubitemid 44222321)
36. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24:7806-19. (Pubitemid 39121503)
37. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-63. (Pubitemid 35408327)
38. Franke RM, Gardner ER, Sparreboom A. Pharmacogenetics of drug transporters. Curr Pharm Des 2010;16:220-30.
39. Lau JP, Weatherdon KL, Skalski V, Hedley DW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 2004;91:1166-73. (Pubitemid 39336258)